Opinion

Video

Payer Coverage Considerations for New Treatments for Alzheimer Disease

Author(s):

Derek van Amerongen, MD, MS,Soeren Mattke, MD, DSc

Experts discuss how payers can prepare for new treatments and plan adequate coverage for patients with Alzheimer disease.

Video content above is prompted by the following question(s):

  • How can plan sponsors effectively prepare for these new treatments and plan coverage in a way that ensure adequate care for patients with Alzheimer disease and availability of coverage for all patients?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
4 experts in this video
4 experts in this video
Related Content
MS ribbon and brain drawing | Image credit: Pixel-Shot - stock.adobe.com
July 16th 2025

Review Highlights Gaps in Transition From Pediatric to Adult MS Care

Skylar Jeremias
Pediatric patients with multiple sclerosis (MS) face significant challenges transitioning to adult care, risking treatment delays and long-term health outcomes.
The primary outcome measure in the ambulatory cohort in the study was mean change from baseline to week 52 in the TTR from floor, and no significant differences were seen between the treatment and control groups. | Image credit: OlegKachura - stock.adobe.com
July 11th 2025

TAS-205 Misses Primary End Point in Phase 3 DMD Trial

Rose McNulty
TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.
While accommodations can improve quality of life for patients with DMD and foster independence, the costs of home and ve modifications fall mostly on the families of patients. | Image credit: Nadzeya - stock.adobe.com
July 10th 2025

Accommodations as DMD Progresses Incur Substantial Household Costs

Rose McNulty
Families caring for individuals with Duchenne muscular dystrophy (DMD) face significant financial burdens from necessary home and vehicle modifications to enhance quality of life.
An analysis of outcomes from part 2 of the EMBARK trial included 14 patients who had received a placebo in part 1 of the study and were aged 8 to 9 years at crossover. | Image Credit: RFBSIP - stock.adobe.com
June 13th 2025

DMD Gene Therapy Shows Clinical Benefits in 8- and 9-Year-Old Patients

Rose McNulty
The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD).
Alzheimer disease. | Image Credit: ipopba - stock.adobe.com
June 5th 2025

Alzheimer Disease and Related Dementias Cause Surging Economic Burden for Minoritized Communities

Cameron Santoro
African American and Latino older adults with Alzheimer disease and related dementias and their families are likely to face disproportionately high burdens, primarily associated with unpaid caregiving, suggesting the need for policies that may reduce economic burdens for all US residents.
While significant progress has been made, innovations in vector design, immune modulation, and delivery strategies are needed to further improve gene therapy for DMD. | Image credit: RFBSIP - stock.adobe.com
May 30th 2025

Hurdles Remain Despite Progress in Gene Therapy for DMD

Rose McNulty
Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo